Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab in Osteopenia Patients After Lumbar Fusion
NCT05415657Completed
- Sponsor
- Shenzhen People's Hospital
- Start
- Jan 2020
- Primary completion
- Jan 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Randomised, double-blind trial in osteopenia comparing Denosumab with Placebo (2 arms). Primary endpoints: Lumbar bone mineral density at 12 months, Total hip bone mineral density at 12 months and 5 more. Started Jan 2020; status: completed.
02
Drugs
denosumab
03
Conditions
osteopenia
Beyond the preview
Go deeper on NCT05415657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05415657.